rheumatology
Spondyloarthritis

Biologic use in AS more than doubles in a decade

A large rise in the use of biologics in ankylosing spondylitis over the last decade can be explained by an increased awareness of inflammatory back pain and a reluctance to stop therapy in patients who have partially responded to treatment, a PBS review concludes. According to an outcomes statement from the the PBS drug utilisation ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic